Company*
(Country; Symbol)

Company*
(Country; Symbol)

Type/Product Area

Terms/Details (Date)

Accentia Biopharmaceuticals Inc. (PK:ABPI)

Baxter Healthcare Corp.

Deal for Accentia to acquire the right to purchase cyclophosphamide for use in its Revimmune therapy for multiple sclerosis and other autoimmune diseases

Accentia will be able to reference Baxter's historical data as part of its clinical development plan (11/30)

Amicus Therapeutics Inc. (FOLD)

GlaxoSmithKline plc (UK)

Partnership for Fabry disease drug Amigal

Amicus will get $60M up front in the potential $230M partnership; GSK is paying $30M in cash and will take a 19.9% equity stake for about $31M, and Amicus is eligible for up to $170M in milestones, plus tiered, double-digit royalties (11/1)

Aposense Ltd. (Israel; TASE:APSN)

Roche AG (Switzerland)

Nonexclusive agreement to use the EarliTest solution with Roche's oncology program

Roche will fund the clinical trials and pay Aposense undisclosed license and milestone fees (11/10)

Archemix Inc.*

Baxter International Inc.

Agreement to sell Arch-emix's hemophlia-related assets to Baxter

Baxter will pay $30M up front and possibly $285M in milestone payments; Baxter gains ARC19499 and related intellectual property assets (11/22)

Biovista Inc.*

Pfizer Inc.

Research collaboration to seek new indications for Pfizer drug candidates in development using a bioinformatics technology platform developed by Biovista

Terms include the identification of up to three new indications for each drug; Biovista will receive an undisclosed up-front payment and success milestone payments (11/10)

Evotec AG (Germany; FSE:EVT)

Merck KGaA (Germany)

Deal to develop preclinical candidates for an undisclosed neurological disease

Evotec will provide drug discovery expertise covering in vitro biology, medicinal chemistry and in vitro and in vivo pharmacology (11/24)

Forma Therapeutics Inc.*

Eisai Inc. (unit of Eisai Co. Ltd.; Japan)

Drug discovery deal that focuses on difficult-to-treat drug targets

Forma gets up-front payments and committed funding of $20M over three years, plus additional milestone payments and royalties on future products that Eisai commercializes (11/18)

f-star Biotechnologische GmbH* (UK)

Boehringer Ingelheim GmbH (Germany)

Partnership to apply its modular antibody technology to discover antibodies and/or antibody fragments against seven targets nominated by Boehringer

F-star gets an up-front fee, research funding and milestone payments; the deal could be worth $245.4M (11/23)

Guangdong Techpool Bio-Pharma Co. Ltd.* (China)

Nycomed A/S (Switzerland)

Nycomed acquired a majority stake in Guangdong by purchasing 51.4% of its shares

The two companies operate as seperate entities; Nycomed will benefit from Techpool's protein drug assets and its market presence in China (11/2)

Simcere Pharmaceutical Group (China; NYSE:SCR)

Bristol-Myers Squibb Co.

Deal to co-develop BMS-817378, a preclinical small-molecule MET/VEGFR-2 inhibitor, to treat cancer

Simcere gains exclusive rights to develop and commercialize the product in China, while BMS retains rights in all other markets (11/4)

Spencer Pharmaceuticals Inc. (PK:SPPH)

National Pharmaceutical Corp.

Agreement to develop central nervous disease treatments for Alzheimer's and Parkinson's diseases using Spencer's drug delivery platform

The companies will swap 20M restricted shares, subject to a final agreement (11/2)

Valeant Pharmaceuticals International Inc. (Canada; NYSE:VRX)

Kadmon Pharmaceuticals LLC

Agreement granting Kad-mon an exclusive worldwide license to taribavirin, excluding Japan; and a deal for exclusive rights to its dosage forms of ribavirin in Poland, Hungary, Czech Republic, Slovakia, Romania and Bulgaria

Valeant gained an up-front payment of $5M plus development milestones and royalties in the range of 8-12% of future net sales; in the second deal, Valeant paid $7.5M for exclusive rights (11/2)

Adamis Pharmaceuticals Corp. (OTC BB:ADMP)

Beximco Pharmaceuticals Ltd. (Bangladesh)

Partnership to introduce four separate drugs in the area of allergy and asthma in the U.S. over three years

The two companies also will co-develop other drugs (12/2)

Anaphore Inc.*

Mitsubishi Tanabe Pharma Corp.

Partnership for Anaphore's Atrimer protein engineering platform

The deal is worth up to $345M, including $5M up front for the initial autoimmune target and $110M in milestones, plus the possibility of two additional targets under the same terms; the deal also includes tiered royalties on future sales (12/13)

Apexigen Inc.*

Johnson & Johnson

Worldwide antibody discover and development deal

Apexigen will generate and screen antibodies to several targets specified by Centocor; terms were not disclosed (12/8)

Ascenta Therapeutics Inc.*

Ascentage Pharma Group Corp. Ltd. (China)

Collaboration to develop cancer candidates AT-101 and AT-406 from Ascenta's pipeline

AT-101 and AT-406 trigger apoptosis through pan-Bcl-2 inhibition and multi-IAP inhibition, respectively (12/2)

Asupex Pharmaceuticals Inc.*

Teva Pharmaceutical Industries Ltd. (Israel)

Deal involving a deuterium-containing drug

Financial terms were not disclosed (12/21)

Avila Therapeutics Inc.*

Sanofi-Aventis SA (France)

Collaboration to design targeted covalent drugs against six signaling proteins with relevance in oncology, with Sanofi moving forward five of the drugs and Avila retaining rights to one

Sanofi-Aventis paid $40M up-front in cash and committed to as much as $770M in milestones (12/21)

Biological Mimetics Inc.*

GlaxoSmithKline plc

Research collaboration to focus on applications of its Immune Refocusing Technology to develop vaccines

Financial terms were not disclosed (12/6)

Cancer Targeted Technology*

Bayer Schering Pharma AG (Germany)

Research and license option agreement to optimize a PET imaging agent based on its inhibitor scaffold that recognizes a validated cancer enzyme biomarker

Financial details were not disclosed (12/15)

CardioVascular BioTherapeutics Inc. (PK:CVBT)

Merck & Co. Inc.

Exclusive licensing agreement for clinical and scientific data regarding the therapeutic use of human fibroblast growth factor-1 to treat diabetic wounds

CVBT plans to use the data to advance its FGF-1 diabetic wound healing drug candidate, CVBT-141B, to a pivotal Phase III trial (12/1)

Champions Biotechnology Inc.*

Teva Pharmaceutical Industries Ltd. (Israel)

Partnership to use its Tumorgraft platform to evaluate an anti-angiogenic drug from Teva

Terms were not disclosed (12/7)

Cytori Therapeutics Inc. (CYTX)

Astellas Pharma Inc. (Japan)

Strategic equity deal for Astellas to purchase 1.43M unregistered shares of Cytori common stock for $7 each

Astellas gets a two-year rights of first refusal on Cytori's adipose stem cell products for use in liver disease as well as a nonvoting board of director's seat and a scientific advisory board seat (12/8)

DiaGenic ASA (Norway; OSLO:DIAG)

Pfizer Inc.

Agreement for an explorative R&D collaboration to identify biomarkers in early stages of Alzheimer's disease using DiaGenic's patented gene expression technology and its blood samples from ongoing clinical studies

The agreement gives Pfizer a nonexclusive, worldwide license to use DiaGenic's MCI test and AD tests in their research and drug development programs (12/20)

Emisphere Technologies Inc. (OTC BB:EMIS)

Novo Nordisk A/S (Denmark)

Oral diabetes drug delivery deal

Emisphere will receive $5M up front and a potential $52.5M in milestones to use its Eligen technology to develop oral formulations of Novo's insulin products (12/22)

EpiTherapeutics Aps* (Denmark)

Abbott

Deal to discover small-molecule inhibitors of epigenetic oncology targets

Financial terms were not disclosed (12/21)

Epitomics Inc.*

SAIC Frederick Inc.

Contract to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technol-ogies for Cancer program

The goal is to develop high affinity and renewable reagents to capture tryptic peptides derived from human plasma protein biomarkers, and then use the captured peptides to quantify the biomarkers (12/16)

Evotec AG (Germany; FSE:EVT)

AstraZeneca plc (UK) subsidiary MedImmune

Partnership for a biologic beta cell regeneration program

The deal is worth $345.2M, with $6.6M at signing, and 30% of the up-front and milestone payments are owed to DeveloGen shareholders; Evotec acquired DeveloGen in July (12/16)

Galenica AG (Switzerland; SWX:GALN)

Fresenius Medical Care AG & Co. KGaA (Germany)

Deal to create renal pharmaceutical company Vifor-Fresenius Medical Care Renal Pharma Ltd.

Galenica will give the newco intravenous iron products Venofer and Ferinject for use in the dialysis and pre-dialysis market as well as rights to a Phase II iron-based phosphate binder (12/2)

GenVec Inc. (GNVC)

Sanofi-Aventis Group SA's Merial animal health division

Deal to use GenVec's adenovector technology to develop and sell a vaccine for foot-and-mouth disease

Specific financial terms were not disclosed (12/30)

Gruenenthal GmbH* (Germany)

Forest Laboratories Inc.

Licensing agreement for Phase II small-molecule analgesic GRT 6005 and follow-on compound GRT 6006 to Forest Laboratories

Forest will pay an up-front fee, milestones and royalties in exchange for U.S. and Canadian rights and a co-promotion option in Europe (12/7)

Gruenenthal GmbH* (Germany)

Forest Laboratories Inc.

Agreement selling the rights to colistin, an antibiotic for cystic-fibrosis-related bacterial infections, and Colobreathe, a delivery device for colistin

Financial terms were not disclosed

LPath Inc. (OTC BB:LPTN)

Pfizer Inc.

Deal covering lead antibodies iSONEP for ophthalmology and ASONEP for cancer

The deal calls for Pfizer to pay LPath $14M up front as well as share half the costs of two planned iSONEP trials; if Pfizer exercises its worldwide option on iSONEP, LPath will get an option fee, up to $497.5M in milestone payments and tiered double-digit royalties, plus a right of first refusal on ASONEP (12/21)

Merrion Pharmaceuticals plc (Ireland; PK:MNHPF)

Undisclosed pharmaceutical company; Novo Nordisk AS (Denmark)

Deal to evaluate whether Merrion's GIPET drug delivery technology can boost the bioavailability of three of the pharma's drugs

Terms were not disclosed (12/7); the second deal is to see if the GIPET technology can boost oral bioavailability with an undisclosed Novo Nordisk compound; Merrion issued warrants for up to $1.96M in Merrion shares at $3.92 per share (12/23)

Novogen Ltd. (Australia; NVGN)

Marshall Edwards Inc.

Deal for Marshall Edwards to acquire isoflavone-based intellectual property

Novogen will receive $4M in convertible preferred stock; each of 1,000 shares of Class A preferred stock is convertible to a minimum of 4,827 shares of common stock (12/23)

PhenoMatriX*

SRI International

Collaboration on the development of platin-based chemotherapies

Platin-based drugs such as cisplatin and related analogues are used to treat a variety of cancers with solid tumors and other difficult-to-treat cancers; SRI will receive royalties and an equity stake once R&D milestones are met (12/6)

Philochem AG* (Switzerland)

Merck Serono (division of Merck KGaA; Germany)

Deal in which Philochem will supply specific monoclonal antibodies to Merck Serono, to be used in the search for molecular biomarkers of oocyte and embryo quality for a test to be used by physicians

Terms were not disclosed (12/22)

Phylogica Ltd. (Australia; ASX:PYC)

Pfizer Inc.

Collaboration and licensing deal to discover peptide-based vaccines

Phylogica will use its Phylomer drug discovery platform, and will receive $500,000 up front and is eligible to receive a commercial license payment, plus milestone payments of up to $134M, as well as royalties (12/21)

Proximagen Ltd. (UK; LSE:PRX)

GlaxoSmithKline plc (UK)

Exclusive agreement to acquire the global rights to two drug development programs that target diseases of the central nervous system

Financial terms were not disclosed (12/22)

Serodus A/S* (Norway)

Roche AG (Switzerland)

License deal for a selective serotonin-4 antagonist for potential treatment of heart failure

Roche will receive an undisclosed up-front payment and will be entitled to development, regulatory and commercial milestones, plus royalties (12/13)

Sirnaomics Inc.*

Undisclosed Chinese pharmaceutical company

Partnership for development of its small interfering RNA therapeutic STP705 for scarless wound healing

The partnership specifically covers the regulatory development and sale of STP705 in the greater China market (12/3)

Sloning BioTechnology GmbH (subisidary of MorphoSys AG; Germany; BE:MOR)

Pfizer Inc.

Nonexclusive license and technology transfer deal covering the installation, training and use of Sloning's Slonomics platform for fabrication of highly diverse gene and protein libraries and Pfizer's subsidiary, Rinat NeuroScience Corp.

Terms call for Sloning to receive an up-front payment this year, with annual license fees due over the patent lifetime (12/13)

Stellar Biotechnologies Inc. (CDNX:KLH)

Bayer Innovations

Exclusive, irrevocable, worldwide sublicensable and royalty-free license to the technology developed through a collaboration between the two

The license includes a carve-out by BIG for use of the technology in its non-Hodgkin lymphoma vaccine, which is currently under development (12/8)

Tesaro Inc.*

OPKO Health Inc.

Deal to acquire rights to nausea drug rolapitant and one other drug from OPKO

Terms entail $121M in up-front and milestone payments, plus double-digit, tiered royalties and a 10% equity position (12/15)

Vernalis plc (UK; LSE:VER)

H. Lundbeck A/S (Denmark)

Partnership to use vernalis' fragment- and structure-based platform against LRRK2

Vernalis will receive undisclosed fees and a potential share in the downstream success of the product in the form of milestones and royalties (12/17)

Zenobia Therapeutics Inc.*

H. Lundbeck A/S (Denmark)

Research collaboration to use Zenobia's expertise in protein expression and X-ray crystallography for the Parkinson's disease target LRRK2

Zenobia will complete X-ray crystal structures of wild-type and the Parkinson's-associated mutant, G20195, in complex with Lundbeck compounds (12/17)

Notes:

* Private companies are indicated with an asterisk. Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

ASX = Australian Stock Exchange; BE = Berlin Stock Exchange; CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; SWX = Swiss Stock Exchange; TASE = Tel Aviv Stock Exchange.